Adam Maeder

Q: What is Adam Maeder's success rate?

Adam Maeder currently has a success rate of 99.47647997193275.

Q: What is the average return of Adam Maeder's calls?

Their stock ratings have generated an average return of 2.8499884585350364.

Piper Sandler | Healthcare

Adam Maeder is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #1494 out of 4643 analysts, they have issued 29 stock ratings with a success rate of 99.48% and an average return of 2.85%.

Adam Maeder has a well-established track record, with 29 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 99.48% and an average return of 2.85%, underscoring their expertise and ability to identify winning opportunities for investors.

#1494

Out of 4643

Total Ratings

+99.48%

Success Rate

+2.85%

Average Return

Recent Ratings Analysis

INSP

Hold

May 05, 2026

Target

$55.00

Current

$44.26

Performance

-8.27%

Adam Maeder rated INSP as Neutral on May 05, 2026, setting a price target of 55. The cautious Hold call aligned with subsequent weakness, as shares slipped 8.27%.

NSPR

Buy

May 05, 2026

Target

$3.00

Current

$1.15

Performance

4.55%

On May 05, 2026, NSPR was given a Overweight rating by Adam Maeder, with a target price of 3. The stock traded sideways with a 4.55% move, keeping the bullish thesis unresolved.

ISRG

Buy

Apr 22, 2026

Target

$580.00

Current

$450.06

Performance

-6.94%

ISRG received a Overweight rating from Adam Maeder on Apr 22, 2026, aiming for 580. The rating hasn’t played out as hoped, with the stock trading 6.94% below expectations.

ABT

Buy

Apr 17, 2026

Target

$115.00

Current

$84.30

Performance

-12.92%

On Apr 17, 2026, Adam Maeder published a Overweight outlook on ABT, with a target of 115. Market action contradicted the Buy thesis, as shares slipped to 84.3.

RXST

Hold

Feb 26, 2026

Target

$11.00

Current

$5.85

Performance

-26.14%

Adam Maeder on Feb 26, 2026 assigned RXST a Neutral rating, with a price target of 11. The call successfully avoided chasing as shares lost 26.14%.

TCMD

Buy

Feb 18, 2026

Target

$42.00

Current

$25.65

Performance

-22.39%

On Feb 18, 2026, Adam Maeder reaffirmed TCMD with a Overweight rating, targeting 42. Shares slid 22.39% despite the recommendation, highlighting downside risks.

EW

Buy

Feb 11, 2026

Target

$100.00

Current

$79.96

Performance

0.79%

EW was rated Overweight by Adam Maeder on Feb 11, 2026, with a price objective of 100. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

RMD

Hold

Jan 30, 2026

Target

$275.00

Current

$206.76

Performance

-19.96%

On Jan 30, 2026, Adam Maeder initiated coverage on RMD with a Neutral rating and target of 275. The rating matched the stock’s inability to hold above 206.76.

SGHT

Buy

Jan 05, 2026

Target

$9.00

Current

$5.38

Performance

-30.22%

Adam Maeder issued a Overweight recommendation for SGHT on Jan 05, 2026, price target set at 9. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

NYXH

Buy

Nov 14, 2025

Target

$9.00

Current

$3.26

Performance

-34.80%

On Nov 14, 2025, NYXH was evaluated by Adam Maeder, who gave a Overweight rating and target of 9. Investors saw limited payoff as shares fell short of the 9 target.

RBOT

Hold

Aug 13, 2025

Target

$7.00

Current

$0.55

Performance

-92.98%

Adam Maeder rated RBOT as Neutral on Aug 13, 2025, setting a price target of 7. The cautious Hold call aligned with subsequent weakness, as shares slipped 92.98%.

NVRO

Hold

Feb 07, 2025

Target

$5.85

Current

$5.84

Performance

2.10%

On Feb 07, 2025, NVRO was given a Neutral rating by Adam Maeder, with a target price of 5.85. Market indecision, reflected in sideways trading near 5.84, supported the cautious call.

NARI

Hold

Jan 07, 2025

Target

$80.00

Current

$79.97

Performance

0.65%

NARI received a Neutral rating from Adam Maeder on Jan 07, 2025, aiming for 80. Shares remained flat at 79.97, aligning with the neutral rating.

SILK

Hold

May 01, 2024

Target

$20.00

Current

$27.49

Performance

36.36%

On May 01, 2024, Adam Maeder published a Neutral outlook on SILK, with a target of 20. The Hold call missed some of the bullish momentum as shares advanced toward 20.

Frequency Asked Questions

Who is Adam Maeder?

Adam Maeder is an analyst from Piper Sandler specializing in the Healthcare sector.

What is Adam Maeder's success rate?

Adam Maeder currently has a success rate of +99.48%.

How many ratings has Adam Maeder issued?

Adam Maeder has issued 29 stock ratings so far.

What is the average return of Adam Maeder's calls?

Their stock ratings have generated an average return of +2.85%.

What is Adam Maeder's ranking?

Adam Maeder is ranked #1494 out of 4643 analysts.

What types of ratings does Adam Maeder give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Adam Maeder?

You can follow Adam Maeder by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Adam Maeder?

Their latest rating was a Hold on INSP issued on 2026-05-05.